Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8⁺ T cell control of tumor challenge in mice.

ABSTRACT:

Background

Neoantigens are promising immunogens for cancer vaccines and are often delivered as adjuvanted peptide vaccines. Adenoviral (Ad) vectors have been shown to induce strong CD8⁺ T cell responses as vaccines against SARS-CoV-2, Ebola, and Zika, but their utility as neoantigen delivery vectors remains largely unexplored. In this study, we examine how an Ad-vectored neoantigen vaccine would impact tumor immunity compared with a peptide neoantigen vaccine.

Methods

We generated Ad serotype 26 (Ad26) vaccine candidates encoding B16-F10-ovalbumin (OVA) and MC38-specific neoantigens. Ad26 vaccines were compared with adjuvanted peptide delivery as prophylactic vaccines in B16-F10-OVA and MC38 challenge models. Immune responses induced by the best Ad26 vaccine (Ad26

SUBMITTER: Dagotto G 

PROVIDER: S-EPMC11660326 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature